These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24730505)

  • 1. Response to the open peer commentaries on "Is there an ethical obligation to disclose controversial risk? A question from the ACCORD Trial".
    DeMarco JP; Ford PJ; Patton DJ; Stewart DO
    Am J Bioeth; 2014; 14(4):W1-2. PubMed ID: 24730505
    [No Abstract]   [Full Text] [Related]  

  • 2. Disclosing controversial risk in informed consent: how serious is serious?
    Kocarnik JM
    Am J Bioeth; 2014; 14(4):13-4. PubMed ID: 24730481
    [No Abstract]   [Full Text] [Related]  

  • 3. The ethical imperative of risk disclosure in research: the answer is always yes.
    Quinn GP; Haura EB; Murphy D
    Am J Bioeth; 2014; 14(4):18-9. PubMed ID: 24730484
    [No Abstract]   [Full Text] [Related]  

  • 4. Equipoise and nonmedical risks.
    Boesch B
    Am J Bioeth; 2014; 14(4):16-8. PubMed ID: 24730483
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenging the requirements for disclosing risk to clinical research participants.
    Markman M
    Am J Bioeth; 2014; 14(4):11-2. PubMed ID: 24730480
    [No Abstract]   [Full Text] [Related]  

  • 6. Disclosure of risks and uncertainties are especially vital in light of regenerative medicine.
    Niemansburg SL; Habets MG; van Delden JJ; Bredenoord AL
    Am J Bioeth; 2014; 14(4):14-6. PubMed ID: 24730482
    [No Abstract]   [Full Text] [Related]  

  • 7. Is there an ethical obligation to disclose controversial risk? A question from the ACCORD Trial.
    DeMarco JP; Ford PJ; Patton DJ; Stewart DO
    Am J Bioeth; 2014; 14(4):4-10. PubMed ID: 24730479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Researchers have an ethical obligation to disclose the availability of off-label marketed drugs.
    Silber TJ
    Am J Bioeth; 2014; 14(4):52. PubMed ID: 24730497
    [No Abstract]   [Full Text] [Related]  

  • 9. Which alternatives should investigators disclose to research subjects?
    Phillips J; Wendler D
    Am J Bioeth; 2014; 14(4):54-5. PubMed ID: 24730499
    [No Abstract]   [Full Text] [Related]  

  • 10. The relevance of research study phase to disclosure of off-label drug availability.
    Baskaran A; Sade RM
    Am J Bioeth; 2014; 14(4):53-4. PubMed ID: 24730498
    [No Abstract]   [Full Text] [Related]  

  • 11. The duty to disclose (even more) adverse clinical trial results.
    Hassoun N
    Am J Bioeth; 2009 Aug; 9(8):33-4. PubMed ID: 19998155
    [No Abstract]   [Full Text] [Related]  

  • 12. The ethics of disclosing to research subjects the availability of off-label marketed drugs.
    Taylor HA; Kuwana E; Wilfond BS
    Am J Bioeth; 2014; 14(4):51. PubMed ID: 24730496
    [No Abstract]   [Full Text] [Related]  

  • 13. Respecting participant autonomy and the disclosure of clinical trial results.
    Oakley J
    Am J Bioeth; 2009 Aug; 9(8):38. PubMed ID: 19998158
    [No Abstract]   [Full Text] [Related]  

  • 14. Disclosure of adverse clinical trial results--should legal immunity be granted to drug companies?
    Vernillo A
    Am J Bioeth; 2009 Aug; 9(8):45-7. PubMed ID: 19998162
    [No Abstract]   [Full Text] [Related]  

  • 15. The duty to disclose adverse clinical trial results.
    Liao SM; Sheehan M; Clarke S
    Am J Bioeth; 2009 Aug; 9(8):24-32. PubMed ID: 19998154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compounding risks to patients: selective disclosure is not an option.
    McGoey L
    Am J Bioeth; 2009 Aug; 9(8):35-6. PubMed ID: 19998156
    [No Abstract]   [Full Text] [Related]  

  • 17. Disclosing clinical trial results: publicity, significance and independence.
    Liao SM; Sheehan M; Clarke S
    Am J Bioeth; 2009 Aug; 9(8):W3-5. PubMed ID: 19998144
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving subject recruitment by maintaining truly informed consent: a practical benefit of disclosing adverse clinical trial results.
    Shah KR; Batzer FR
    Am J Bioeth; 2009 Aug; 9(8):36-7. PubMed ID: 19998157
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancing informed consent in clinical trials and exploring resistances to disclosing adverse clinical trial results.
    Banja JD; Dunlop B
    Am J Bioeth; 2009 Aug; 9(8):39-41. PubMed ID: 19998159
    [No Abstract]   [Full Text] [Related]  

  • 20. Precautionary harm disclosure in clinical trials.
    Wu KC
    Am J Bioeth; 2009 Aug; 9(8):43-5. PubMed ID: 19998161
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.